Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23][24] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at over $16.6 billion today and is projected to grow at a CAGR of 8.6% to $34.8 billion by 2033 [15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [34] Question: Can you talk about the previous guidance given on last conference call? - Management indicated that previous guidance was around $2 million-$2.5 million for fiscal year, but recent sales trends have affected expectations [37][38] Question: Are you pushing out the uptick in sales? - Management clarified that the sales model has changed, and they are focusing on spreading sales more evenly across quarters [40] Question: Can you talk about the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is streamlined, and CapEx is minimal as Digital Landia will handle most of the implementation [42][51] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system and benefit from cost savings [46] Question: Do you have expectations for revenues and PNL? - Management refrained from providing specific revenue guidance at this time [52][53]

Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same period a year ago [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from $812,000, or 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents per share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at more than $16.6 billion today and is projected to double to $34.8 billion by 2033, growing at a CAGR of 8.6% [14][15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for the duration of fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards listing on New York AMEX, with stock price being a factor in the timeline [34] Question: Previous guidance on revenue - Management indicated that previous guidance was around $2 million-$2.5 million for the fiscal year, but recent sales trends have affected expectations [37][38] Question: CapEx for the rollout of the Digital Landia platform - The onboarding of veterinarians will be part of the current clinics, with minimal CapEx required as Digital Landia will handle the system updates [42][51] Question: Revenue expectations from the implementation of the PetVivo.ai system - Management confirmed that revenues will be recognized from veterinarians implementing the system, which operates on a SaaS model [46][48]

Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months totaled $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [21] - Total liabilities decreased by 81% to $1 million on December 31, down from $5.1 million on March 31 [23] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - Gross margins for the PrecisePRP product line were lower, impacting overall gross profit [19] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [24] - The European animal health market is estimated at over $16.6 billion today and is projected to double to $34.8 billion by 2033, growing at a CAGR of 8.6% [15] Company Strategy and Development Direction - The company is focusing on creating strong recurring revenues and market expansion opportunities through new product launches and strategic partnerships [2] - A new AI-powered software as a service platform, PetVivo AI, is being launched to enhance veterinary practices and reduce customer acquisition costs [4][5] - The company is advancing its product pipeline, including new functional biomaterials for regenerative applications [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued sales momentum and market penetration for the remainder of fiscal 2026 and beyond [30] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [30] - Management highlighted the importance of educating customers on the combined use of Spryng and PrecisePRP to drive future sales [18] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Digital Landia aims to address challenges in the veterinary industry and enhance customer engagement through AI technology [3] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [33] Question: Can you talk about the previous guidance given on last conference call? - Management noted that previous guidance was not recalled, but acknowledged that sales were affected by changes in promotional strategies [36][38] Question: Can you discuss the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is designed to be efficient, with minimal CapEx required from the company [41][50] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system [45] Question: Do you have expectations for revenues and PNL in the next year? - Management refrained from providing specific revenue guidance at this time [52]

Revenue Performance - Revenues for the three months ended December 31, 2025, were $286,108, a decrease from $583,313 in the same period of 2024, primarily due to a lack of promotional discounts offered in December 2025 [145] - Total revenues for the nine months ended December 31, 2025, were $886,892, down from $907,783 in 2024, with sales of Spryng® products at $400,711 and PrecisePRP™ products at $486,181 [153] Cost of Sales - Cost of sales increased to $141,396 in Q3 2025 from $61,497 in Q3 2024, attributed to lower-margin purchases of PrecisePRP™ products [146] - Cost of sales increased to $335,396 for the nine months ended December 31, 2025, from $95,653 in 2024, due to lower-margin purchases associated with PrecisePRP™ products [154] Operating Expenses - Operating expenses rose to $2,336,167 in Q3 2025 compared to $2,280,221 in Q3 2024, driven by higher general and administrative and sales and marketing expenses [147] - Operating expenses decreased to $6,652,635 for the nine months ended December 31, 2025, from $6,788,008 in 2024, mainly due to lower general and administrative and R&D expenses [155] General and Administrative Expenses - General and administrative expenses were $1,252,406 in Q3 2025, up from $1,184,807 in Q3 2024 [148] Sales and Marketing Expenses - Sales and marketing expenses increased to $760,770 in Q3 2025 from $723,461 in Q3 2024, supporting the launch of Spryng® and PrecisePRP™ products [149] Research and Development Expenses - Research and development (R&D) expenses decreased to $322,991 for the three months ended December 31, 2025, from $371,953 in 2024, primarily due to decreased clinical studies [150] Profitability and Loss - The operating loss for the three months ended December 31, 2025, was $2,191,455, compared to $1,758,405 in 2024, attributed to decreased revenues [150] - Net loss for the three months ended December 31, 2025, was $2,191,455 or ($0.07) per share, compared to a net loss of $1,757,038 or ($0.09) per share in 2024, driven by decreased sales and increased expenses [152] Cash Flow and Capital Needs - Net cash used in operating activities was $5,294,904 for the nine months ended December 31, 2025, primarily due to the net loss of $7,510,301 [163] - The company anticipates needing to raise additional capital to support operations and commercialize products, with a recent private placement generating $5,000,000 [162] Current Assets and Liabilities - As of December 31, 2025, current assets were $1,383,278, with current liabilities of $988,421, resulting in working capital of $394,857 [161] Going Concern - The report expresses substantial doubt about the company's ability to continue as a going concern, highlighting minimal cash position and ongoing losses [167] Product Information - Sales of Spryng® products contributed $65,566 to revenues in Q3 2025, while PrecisePRP™ products accounted for $220,542 [145] - Spryng® is priced between $600 to $900 per joint and typically lasts for at least 12 months, providing an effective solution for osteoarthritis [136] - The company has entered into an exclusive licensing agreement with VetStem, Inc. for the sale of PrecisePRP™ products, which guarantees a consistent dose of 4 billion platelets per vial [135] - Osteoarthritis affects approximately 14 million dogs and 1 million horses in a $11 billion market, highlighting the significant opportunity for Spryng® [129] Future Growth Potential - The company has a pipeline of therapeutic devices for both veterinary and human clinical applications, anticipating growth through acquisitions or in-licensing [141]

Core Insights - PetVivo Holdings, Inc. reported financial and operational results for the third quarter and first nine months of fiscal year 2026, highlighting significant advancements in its product offerings and market strategies [1][40]. Fiscal Q3 Operational Highlights - The company launched PetVivo.ai, an AI-powered Software-as-a-Service platform for veterinarians, which has shown a 50% to 90% reduction in customer acquisition costs, decreasing from $80-$400 to less than $43 per target [4][16]. - An exclusive 10-year white-label licensing agreement was signed with Digital Landia for the AgenticPet AI technology, aimed at addressing challenges in the veterinary industry, particularly for Gen Z pet parents [6][15]. - The company completed Stage B of a joint R&D project with PiezoBioMembrane, confirming the mass production capability of a combined product with therapeutic benefits for animals and humans [5][28]. Product Development and Market Expansion - Health Canada acknowledged PetVivo's Spryng with OsteoCushion Technology as a veterinary medical device, opening a new market opportunity in Canada, with plans for a commercial launch in Q3 2026 [8][34]. - The company is advancing its collaboration with Veterinary Growth Partners (VGP) to promote its products to over 7,300 veterinary clinics in the U.S. [26][27]. - PetVivo's products, including Spryng and PrecisePRP, have received favorable feedback from veterinarians, particularly for managing osteoarthritis in animals [33][31]. Financial Performance - For the quarter ended December 31, 2025, the company reported revenues of $286,108, with a gross profit of $144,712, leading to an operating loss of $2,191,455 [55]. - The net loss available to common stockholders for the same period was $2,316,455, translating to a net loss per share of $0.07 [55]. Future Outlook - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing strong growth opportunities for PetVivo [38]. - The company is in advanced discussions with a sales and marketing firm to enhance its distribution network and market penetration [39].

MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, today announced that it is retracting and replacing its previously issued press release dated February 9, 2026 regarding the Company’s fiscal third quarter 2026 conference call. This press release supersedes in it ...

Core Viewpoint - PetVivo Holdings, Inc. will hold a conference call on February 16, 2026, to discuss its fiscal third quarter results for the period ending December 31, 2025 [1][2]. Group 1: Conference Call Details - The conference call is scheduled for February 16, 2026, at 5:00 p.m. Eastern time [2]. - A toll-free dial-in number and conference ID are provided for participants [2]. - A replay of the conference call will be available through a webcast link [3]. Group 2: Company Overview - PetVivo Holdings, Inc. focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for veterinary applications [4]. - The company has a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5]. - Key products include SPRYNG with OsteoCushion technology for joint-related afflictions and PrecisePRP, a first-in-class platelet-rich plasma product [5].

Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]

Core Viewpoint - PetVivo Holdings, Inc. is actively participating in the DealFlow Discovery Conference scheduled for January 28-29, 2026, highlighting its commitment to engaging with investors and showcasing its innovations in medical devices and biomedical therapeutics for animals [1] Company Participation - The company will be represented by John Lai, the Chief Executive Officer, who will deliver a presentation and be available for one-on-one investor meetings during the conference [1]

Core Insights - PetVivo.ai has launched a video to explain its AI-powered platform for veterinary practices, aiming to simplify communication and enhance understanding of its services [1][2][4] - The platform connects pet parents with veterinary practices through a two-sided ecosystem, utilizing 10 specialized AI agents to facilitate client acquisition and health tracking [3][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, focusing on innovative medical devices and therapeutics for companion animals [8] - The company leverages human therapies for animal treatment, aiming for a quicker market entry compared to pharmaceuticals [8] - PetVivo has a diverse product pipeline, including patented technologies for managing joint-related afflictions in animals [9] Product and Service Details - The platform features a freemium model, starting with a free tier, to engage veterinary practices and pet parents [6] - Key products include SPRYNG with OsteoCushion technology for joint management and PrecisePRP, a platelet-rich plasma product for veterinary use [9]